Loading...

James Yang, MD

Title(s)CLINICAL FELLOW, Dean's Office
SchoolSchool of Medicine
Address155 N Fresno St
Fresno CA 93701
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer. 2021 Feb 06; 154:92-98. Park K, Özgüroglu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F. PMID: 33636453.
      View in: PubMed   Mentions:    Fields:    
    2. Circulating Exosomal Integrin ß3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study. Cancers (Basel). 2021 Jan 20; 13(3). Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. PMID: 33498505.
      View in: PubMed   Mentions:
    3. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2021 Jan 13; 13(2). Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang JC. PMID: 33450879.
      View in: PubMed   Mentions:
    4. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2020 Nov 26. Nazha B, Yang JC, Owonikoko TK. PMID: 33242257.
      View in: PubMed   Mentions:    Fields:    
    5. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 Jan; 16(1):162-168. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. PMID: 33069888.
      View in: PubMed   Mentions:    Fields:    
    6. Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Oct 12. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. PMID: 33046516.
      View in: PubMed   Mentions:    Fields:    
    7. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020 Nov 10; 38(32):3805-3815. PMID: 33021872.
      View in: PubMed   Mentions:    Fields:    
    8. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 12; 15(12):1907-1918. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. PMID: 32916310.
      View in: PubMed   Mentions:    Fields:    
    9. Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer. 2020 10; 148:177-178. Lin YT, Yang JC, Chu CY. PMID: 32933772.
      View in: PubMed   Mentions:    Fields:    
    10. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020 Dec; 16(34):2799-2808. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Märten A, Cufer T. PMID: 32854536.
      View in: PubMed   Mentions:    Fields:    
    11. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 01; 38(31):3592-3603. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. PMID: 32780660.
      View in: PubMed   Mentions: 3     Fields:    
    12. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020; 12:1758835920946156. Wu SG, Yu CJ, Yang JC, Shih JY. PMID: 32843903.
      View in: PubMed   Mentions:
    13. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020 11; 8(11):1132-1143. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC. PMID: 32479794.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    14. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 Jul 20; 38(21):2369-2379. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüs M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR. PMID: 32468956.
      View in: PubMed   Mentions: 11     Fields:    
    15. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. PMID: 32469185.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    16. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist. 2020 Aug; 25(8):702-711. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 32386255.
      View in: PubMed   Mentions: 1     Fields:    
    17. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 31; 12(4). Hung PS, Huang MH, Kuo YY, Yang JC. PMID: 32244355.
      View in: PubMed   Mentions:
    18. Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clin Transl Radiat Oncol. 2020 May; 22:76-82. Yang WC, Hsu FM, Chen YH, Shih JY, Yu CJ, Lin ZZ, Lu SH, Yang JC, Cheng AL, Kuo SH. PMID: 32280792.
      View in: PubMed   Mentions:
    19. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020 04; 122(9):1324-1332. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. PMID: 32161368.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 03; 21(3):373-386. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. PMID: 32027846.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    21. Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2020 01 27; 71:117-136. Yang CY, Yang JC, Yang PC. PMID: 31986082.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020 06; 8(6):561-572. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. PMID: 31954624.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    23. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020 05; 15(5):803-815. Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. PMID: 31931137.
      View in: PubMed   Mentions: 11     Fields:    
    24. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 02 20; 38(6):538-547. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. PMID: 31809241.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    25. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019; 11:1758835919890286. Liao BC, Griesing S, Yang JC. PMID: 31803256.
      View in: PubMed   Mentions:
    26. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020 01; 124:110-122. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 31760310.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019; 10:125-130. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. PMID: 32009824.
      View in: PubMed   Mentions:
    28. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020 03; 15(3):324-343. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. PMID: 31733357.
      View in: PubMed   Mentions: 2     Fields:    
    29. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 01; 139:22-27. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. PMID: 31706099.
      View in: PubMed   Mentions: 1     Fields:    
    30. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. J Thorac Oncol. 2020 01; 15(1):91-100. Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. PMID: 31605797.
      View in: PubMed   Mentions: 1     Fields:    
    31. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol. 2020 Jan; 59(1):96-100. Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK. PMID: 31552770.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 01; 15(1):50-61. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JC. PMID: 31557536.
      View in: PubMed   Mentions: 7     Fields:    
    33. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019 10 20; 37(30):2759-2768. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. PMID: 31408414.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    34. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep; 15(25):2905-2914. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T. PMID: 31370698.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2020 Jan; 52(1):284-291. Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. PMID: 31345012.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    36. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 08; 117:107-115. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. PMID: 31279301.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    37. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019 Jul; 15(20):2371-2383. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. PMID: 31354046.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 12; 24(12):e1417-e1425. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. PMID: 31127020.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019 07; 133:103-109. Liang SK, Ko JC, Yang JC, Shih JY. PMID: 31200815.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 05; 42(4):126-135. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. PMID: 30882547.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    41. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol. 2019; 11:1758835919836374. Park K, Wan-Teck Lim D, Okamoto I, Yang JC. PMID: 31019567.
      View in: PubMed   Mentions:
    42. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019 06; 132:126-131. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. PMID: 31097085.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    43. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019 07; 133:10-19. Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. PMID: 31200814.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    44. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 05; 20(5):602-603. Yang JC. PMID: 30975629.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun; 118(6):995-1004. Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY, Chiang DL, Wu HD, Yang JC, Yu CJ. PMID: 30857753.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020 02; 38(1):99-110. Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. PMID: 30825104.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    47. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1569-1579. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. PMID: 30783814.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    48. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019 05; 14(5):933-939. PMID: 30763730.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    49. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 02; 14(1):57-65. Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. PMID: 30725402.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    50. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. PMID: 30485437.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    51. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 03; 14(3):553-559. Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A. PMID: 30529597.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    52. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. PMID: 30512189.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    53. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov; 14(27):2861-2874. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T. PMID: 30336693.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    54. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 11 22; 379(21):2027-2039. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. PMID: 30280657.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    55. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 11 01; 36(31):3101-3109. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. PMID: 30156984.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    56. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. PMID: 30429032.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    57. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):124-129. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. PMID: 30138764.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    58. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes Cancer. 2018 10; 57(10):513-521. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. PMID: 30107055.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018 Sep; 109(9):2852-2862. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. PMID: 29972716.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    60. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. J Thorac Oncol. 2018 12; 13(12):1897-1905. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC. PMID: 30096481.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    61. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncol. 2018 08 01; 4(8):1138-1139. Gebski V, Yang JC, Lee CK. PMID: 29931217.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. J Immunother. 2018 Jun; 41(5):241-247. Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. PMID: 29672342.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    63. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018 06; 19(8):851-864. Liao BC, Lin CC, Yang JC. PMID: 29726292.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med Assoc. 2019 Jan; 118(1 Pt 2):230-236. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. PMID: 29709339.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018; 9(10):1813-1820. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. PMID: 29805708.
      View in: PubMed   Mentions:
    66. Real-World or Controlled Clinical Trial Data in Real-World Practice. J Thorac Oncol. 2018 04; 13(4):470-472. PMID: 29576285.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clin Drug Investig. 2018 Apr; 38(4):319-331. PMID: 29247383.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 05 10; 36(14):1405-1411. PMID: 29596029.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    69. The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018 06; 13(6):792-800. Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Yang JC. PMID: 29580950.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018 02; 11(1):131-141. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. PMID: 29178024.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    71. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):210-216. PMID: 29270615.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    72. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC. PMID: 29477365.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC. PMID: 29249325.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    74. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018 01; 118(1):38-42. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI. PMID: 29149104.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    75. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. PMID: 29118262.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    76. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2018 Feb; 126(2):368-374. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. PMID: 29111173.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    77. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. PMID: 29056570.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    78. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. PMID: 28968167.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    79. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10; 35(32):3662-3670. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. PMID: 28902534.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    80. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 20; 36(9):841-849. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA. PMID: 28841389.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCTClinical Trials
    81. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329. Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. PMID: 28809608.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    82. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA. PMID: 28751247.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    83. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 09; 82:27-33. PMID: 28646771.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    84. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1552-1560. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. PMID: 28689043.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    85. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):27-34. Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. PMID: 28743421.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    86. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. PMID: 28687375.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    87. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017 Jun 20; 8(25):41474-41486. PMID: 28467813.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    89. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017 06 01; 109(6). PMID: 28376144.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    90. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. J Thorac Oncol. 2017 08; 12(8):1247-1256. PMID: 28527899.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    91. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 08; 110:7-13. PMID: 28676222.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    92. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 07; 12(7):1061-1070. PMID: 28428148.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    93. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 01; 35(16):1803-1813. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. PMID: 28291388.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    94. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    95. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med. 2017 03 01; 195(5):663-673. PMID: 27669169.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    96. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296. PMID: 28221867.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCTClinical Trials
    97. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep. 2017 Jan; 19(1):4. PMID: 28138934.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    98. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):324-332.e1. PMID: 28089594.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    99. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017 Jan 17; 116(2):175-185. PMID: 28006816.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    100. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 04; 12(4):633-643. PMID: 28007626.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    101. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 01; 11(1):51-55. PMID: 27927060.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    102. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 12 07; 8(368):368ra172. PMID: 27928026.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    103. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. J Clin Oncol. 2017 02 20; 35(6):694-695. PMID: 27918723.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol. 2017 03; 12(3):567-572. PMID: 27923714.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    105. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016 Dec 03; 23(1):86. PMID: 27912760.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    106. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud. 2016 11; 2(6):a001263. PMID: 27900369.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    107. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 12; 34(34):4079-4085. PMID: 27863201.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    108. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1251-1257. PMID: 27737606.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    109. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017 02; 12(2):403-407. PMID: 27765535.
      View in: PubMed   Mentions: 159     Fields:    Translation:Humans
    110. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508. PMID: 27745820.
      View in: PubMed   Mentions: 372     Fields:    Translation:HumansCTClinical Trials
    111. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207. PMID: 27729297.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    112. Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Rep Oncol. 2016 May-Aug; 9(2):474-480. PMID: 27721771.
      View in: PubMed   Mentions:
    113. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 09 20; 34(27):3258-66. PMID: 27507876.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    114. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. J Thorac Oncol. 2016 10; 11(10):1736-44. PMID: 27448761.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    115. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct 15; 22(20):5130-5140. PMID: 27435396.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansAnimalsCells
    116. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. J Cancer. 2016; 7(11):1515-23. PMID: 27471567.
      View in: PubMed   Mentions:
    117. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 10 01; 34(28):3375-82. PMID: 27354477.
      View in: PubMed   Mentions: 205     Fields:    Translation:HumansCTClinical Trials
    118. Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 2016 Jul; 15(7):993-1000. PMID: 27212579.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    119. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016 07 10; 34(20):2389-97. PMID: 27217459.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    120. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. J Thorac Oncol. 2016 07; 11(7):1140-52. PMID: 27094798.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    121. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 05; 17(5):577-89. PMID: 27083334.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansCTClinical Trials
    122. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 09; 17(5):e77-e94. PMID: 27130468.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    123. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016 Mar 15; 7(11):12404-13. PMID: 26862733.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    124. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016 Apr; 94:46-53. PMID: 26973206.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    125. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3):380-90. PMID: 26823294.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    126. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015; 10(12):e0145936. PMID: 26720170.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    127. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar; 11(3):370-9. PMID: 26725183.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    128. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clin Lung Cancer. 2016 Mar; 17(2):150-60. PMID: 26809984.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    129. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015 Dec; 10(12):1745-53. PMID: 26743856.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    130. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015 Dec; 10(12):1754-61. PMID: 26334749.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    131. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 01; 34(7):661-8. PMID: 26598747.
      View in: PubMed   Mentions: 181     Fields:    Translation:HumansCTClinical Trials
    132. Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer J. 2015 Nov-Dec; 21(6):506-9. PMID: 26588684.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    133. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015 Sep; 7(5):274-90. PMID: 26327925.
      View in: PubMed   Mentions:
    134. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thorac Oncol. 2015 Sep; 10(9):e95-e96. PMID: 26291023.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    135. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist. 2015 Sep; 20(9):1051-7. PMID: 26240133.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    136. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8):990-8. PMID: 26159065.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    137. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7):830-8. PMID: 26051236.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCTClinical Trials
    138. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 2015 Apr 30; 6(12):10415-31. PMID: 25871388.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    139. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1689-99. PMID: 25923549.
      View in: PubMed   Mentions: 533     Fields:    Translation:HumansCTClinical Trials
    140. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20; 33(18):2092-9. PMID: 25918278.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCells
    141. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015 Jun 10; 33(17):1958-65. PMID: 25897154.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    142. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10; 33(14):1543-50. PMID: 25823737.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansCells
    143. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One. 2015; 10(3):e0119135. PMID: 25807554.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    144. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer. 2015 May; 88(2):208-14. PMID: 25773866.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    145. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Mar; 27(2):94-101. PMID: 25611025.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    146. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb; 16(2):141-51. PMID: 25589191.
      View in: PubMed   Mentions: 407     Fields:    Translation:HumansCTClinical Trials
    147. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014 Nov; 9(11):1720-5. PMID: 25436806.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    148. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar; 16(2):137-43. PMID: 25450871.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    149. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. J Geriatr Oncol. 2015 Jan; 6(1):38-45. PMID: 25245172.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    150. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Sep; 9(9):1385-92. PMID: 25057939.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    151. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7. PMID: 25122437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    152. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20; 33(6):540-9. PMID: 25154820.
      View in: PubMed   Mentions: 492     Fields:    Translation:HumansCellsCTClinical Trials
    153. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014 Aug; 9(8):1171-9. PMID: 25157770.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    154. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep; 50(13):2219-30. PMID: 24953333.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    155. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung Cancer. 2014 Aug; 85(2):230-8. PMID: 24929780.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    156. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8):2484-9. PMID: 24756814.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    157. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10; 32(8):863-4. PMID: 24493734.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    158. Reply to F. De Marinis et al. J Clin Oncol. 2014 Mar 10; 32(8):865. PMID: 24493733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 01; 120(9):1426-32. PMID: 24474396.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    160. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May; 15(3):173-81. PMID: 24486058.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    161. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014 Feb; 83(2):174-81. PMID: 24361280.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    162. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One. 2013; 8(11):e80276. PMID: 24244668.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    163. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec; 82(3):420-5. PMID: 24183104.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsPHPublic Health
    164. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34. PMID: 24101054.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    165. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct; 115(1):61-70. PMID: 23817810.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    166. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-34. PMID: 23816960.
      View in: PubMed   Mentions: 842     Fields:    Translation:HumansCTClinical Trials
    167. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013 Jul; 9(7):991-1003. PMID: 23837762.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    168. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3342-50. PMID: 23816967.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    169. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013 Jun 10; 31(17):2152-9. PMID: 23650429.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCellsCTClinical Trials
    170. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol. 2013 Jun; 14(7):564-5. PMID: 23639469.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    171. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013 May 01; 105(9):595-605. PMID: 23594426.
      View in: PubMed   Mentions: 160     Fields:    Translation:Humans
    172. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013 Aug; 81(2):280-7. PMID: 23540718.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    173. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. PMID: 23506556.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    174. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013 Mar; 73(4):357-69. PMID: 23479407.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    175. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb; 8(2):229-37. PMID: 23328549.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    176. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):418-24. PMID: 23291258.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    177. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013 Feb; 7(1):112-20. PMID: 23102728.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    178. Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Transl Lung Cancer Res. 2012 Sep; 1(3):227-9. PMID: 25806186.
      View in: PubMed   Mentions:
    179. Small-cell lung cancer treatment: where is the target? J Thorac Oncol. 2012 Sep; 7(9):1327-8. PMID: 22895135.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    180. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 01; 328(1):144-51. PMID: 22935675.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    181. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013 Jan; 49(1):106-14. PMID: 22897841.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    182. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study. Oncologist. 2012; 17(10):1294-302. PMID: 22826374.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    183. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33. PMID: 22773810.
      View in: PubMed   Mentions: 184     Fields:    Translation:HumansCells
    184. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012 Jun; 7(6):973-81. PMID: 22551904.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    185. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug; 77(2):346-52. PMID: 22534669.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    186. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012 Jun 15; 18(12):3470-7. PMID: 22510346.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    187. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May; 13(5):528-38. PMID: 22452896.
      View in: PubMed   Mentions: 308     Fields:    Translation:HumansCTClinical Trials
    188. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13(5):539-48. PMID: 22452895.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCTClinical Trials
    189. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 01; 18(7):2039-47. PMID: 22271879.
      View in: PubMed   Mentions: 180     Fields:    Translation:Humans
    190. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012; 82(1):19-24. PMID: 22269348.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    191. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012 Feb 01; 30(4):433-40. PMID: 22215752.
      View in: PubMed   Mentions: 165     Fields:    Translation:Humans
    192. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011 Nov; 6(11):1872-80. PMID: 22011650.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    193. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011 Oct 07; 11:430. PMID: 21982342.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    194. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011 Oct; 6(10):1663-9. PMID: 21869714.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    195. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    196. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20; 29(21):2866-74. PMID: 21670455.
      View in: PubMed   Mentions: 462     Fields:    Translation:HumansCTClinical Trials
    197. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J Immunother. 2011 May; 34(4):397-402. Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. PMID: 21499128.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    198. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul 01; 17(13):4550-7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. PMID: 21498393.
      View in: PubMed   Mentions: 670     Fields:    Translation:HumansCellsCTClinical Trials
    199. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 01; 29(7):917-24. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. PMID: 21282551.
      View in: PubMed   Mentions: 551     Fields:    Translation:HumansCellsCTClinical Trials
    200. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs. 2011 Jan 01; 71(1):79-88. Lin CC, Yang JC. PMID: 21175241.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    201. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010 Oct; 33(8):840-7. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. PMID: 20842052.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    202. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct; 33(8):828-33. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. PMID: 20842054.
      View in: PubMed   Mentions: 316     Fields:    Translation:HumansCTClinical Trials
    203. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010 Jan; 17(1):163-70. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. PMID: 19777192.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    204. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008 Oct; 13(10):1055-62. Stein WD, Yang J, Bates SE, Fojo T. PMID: 18827177.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    205. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10; 26(32):5233-9. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. PMID: 18809613.
      View in: PubMed   Mentions: 518     Fields:    Translation:HumansCellsCTClinical Trials
    206. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008 Jul 15; 113(2):293-301. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. PMID: 18457330.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    207. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec; 30(8):825-30. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. PMID: 18049334.
      View in: PubMed   Mentions: 211     Fields:    Translation:HumansCTClinical Trials
    208. Immunotherapy for renal cell cancer. J Clin Oncol. 2006 Dec 10; 24(35):5576-83. Yang JC, Childs R. PMID: 17158543.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    209. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20; 24(15):2283-9. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. PMID: 16710025.
      View in: PubMed   Mentions: 214     Fields:    Translation:Humans
    210. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005 Sep 01; 23(25):6043-53. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. PMID: 16087944.
      View in: PubMed   Mentions: 263     Fields:    Translation:HumansCTClinical Trials
    211. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 01; 23(10):2346-57. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. PMID: 15800326.
      View in: PubMed   Mentions: 545     Fields:    Translation:HumansCellsCTClinical Trials
    212. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep; 10(9):909-15. Rosenberg SA, Yang JC, Restifo NP. PMID: 15340416.
      View in: PubMed   Mentions: 828     Fields:    Translation:HumansCells
    213. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004 Jul-Aug; 27(4):259-64. Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. PMID: 15235386.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    214. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003 Sep-Oct; 26(5):385-93. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. PMID: 12973027.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    215. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003 Aug 15; 21(16):3127-32. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. PMID: 12915604.
      View in: PubMed   Mentions: 169     Fields:    Translation:HumansCTClinical Trials
    216. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31; 349(5):427-34. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. PMID: 12890841.
      View in: PubMed   Mentions: 629     Fields:    Translation:HumansCTClinical Trials
    217. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1637-43. Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. PMID: 12365010.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    218. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):142-52. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. PMID: 11773163.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCellsCTClinical Trials
    James's Networks
    Concepts (459)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _